Ivabradine Brillpharma

Active Ingredient:: Ivabradine
Origin:: EU

Ivabradine Brillpharma (Ivabradine)

Q: What is Ivabradine Brillpharma used for?

Ivabradine Brillpharma is prescribed to lower heart rate in adults with chronic stable angina and in patients with heart failure with reduced ejection fraction. By reducing the rate at which the heart beats, it helps relieve angina symptoms and may decrease hospitalizations in eligible heart‑failure patients.

Q: How does Ivabradine work?

Ivabradine selectively blocks the funny (If) current carried by HCN channels in the sinoatrial node. Inhibition of this inward sodium/potassium current slows spontaneous depolarisation, which reduces the heart’s pacing without affecting contractile force, blood pressure, or atrioventricular conduction.

Q: What is the usual dose of Ivabradine Brillpharma?

The exact dose of Ivabradine Brillpharma is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate target, and tolerance. Dosage may be adjusted during therapy, and any changes should follow the prescriber’s instructions and local labeling.

Q: Is Ivabradine safe in pregnancy or breastfeeding?

Safety data for Ivabradine during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless specifically indicated by a qualified healthcare professional.

Q: How do I order Ivabradine Brillpharma from GNH India?

To request Ivabradine Brillpharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Ivabradine compare with beta‑blockers?

Both Ivabradine and beta‑blockers lower heart rate, but Ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and also reduce contractile force. Ivabradine may be added when beta‑blockers are insufficient or not tolerated.

Q: How should Ivabradine be stored?

Store Ivabradine Brillpharma at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, direct sunlight and excessive heat to maintain product stability.

Q: How is Ivabradine administered?

Ivabradine Brillpharma is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Dosing times are typically spaced 12 hours apart, but the exact schedule is set by the prescribing clinician.

Q: What are the most serious risks to watch for while taking Ivabradine?

The most serious adverse events include severe symptomatic bradycardia, atrial fibrillation, and marked hypotension. Patients should be instructed to report any unusually slow heart rate, fainting, palpitations, or sudden drops in blood pressure promptly to their healthcare provider.

Q: Who should not use Ivabradine?

Ivabradine is contraindicated in patients with severe hypotension (systolic BP < 90 mmHg), sick sinus syndrome, second‑ or third‑degree atrioventricular block, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to the drug.

Ivabradine, the active ingredient in Ivabradine Brillpharma, is an If channel inhibitor presented as an oral formulation for oral use. It reduces heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH India supplies Ivabradine Brillpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. This includes batch release certificates and stability data to support import requirements.

Manufacturer / TM Owner

Brillpharma (Ireland) Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, thereby lowering heart rate without affecting contractility, which is valuable in certain cardiovascular diseases.

Chronic stable angina: reduces the frequency of angina attacks, improves exercise capacity, and may decrease the need for additional anti‑ischemic medications.
Heart failure with reduced ejection fraction: lowers resting heart rate, diminishes myocardial oxygen demand, and contributes to reduced hospitalization rates in eligible patients.
Stable coronary artery disease: assists in symptom control by decreasing heart‑rate‑related oxygen consumption, complementing other anti‑anginal therapies.

How It Works

Ivabradine binds selectively to the hyperpolarization‑activated cyclic nucleotide‑gated (HCN) channels that generate the funny (If) current in sinoatrial node cells. By inhibiting this inward sodium/potassium current, the drug slows spontaneous depolarization, resulting in a reduction of heart rate without altering myocardial contractility, atrioventricular conduction, or blood pressure. The effect is dose‑dependent and reversible, allowing heart rate to return toward baseline after discontinuation.

Side Effects

Ivabradine may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects

Visual disturbances (phosphenes): transient luminous phenomena.
Bradycardia: resting heart rate below 50 bpm.
Headache.
Dizziness.

Serious or Rare Side Effects

Severe symptomatic bradycardia requiring medical intervention.
Atrial fibrillation.
Hypotension.

Precautions & Warnings

When prescribing Ivabradine, clinicians should consider several precautionary measures to ensure patient safety.

Baseline heart rate assessment: confirm resting heart rate ≥ 60 bpm before initiation.
Contraindication in severe hypotension: avoid use in patients with systolic BP < 90 mmHg.
Caution in sick sinus syndrome: do not use in patients with known sinus node dysfunction.
Hepatic impairment: dose adjustment may be required in moderate to severe liver disease.
Drug interactions: review concomitant use of strong CYP3A4 inhibitors or other bradycardic agents.
Store at ambient temperature: keep tablets in original packaging, protect from moisture and heat.

Avoid Interactions

Ivabradine interacts with several medicines, some of which require avoidance and others close monitoring.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase plasma levels.
Other heart‑rate‑lowering drugs (beta‑blockers, digoxin, diltiazem): risk of excessive bradycardia.
Concomitant use with drugs that prolong AV conduction (e.g., verapamil): may cause conduction disturbances.

Moderate Interactions (Monitor Closely)

Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may raise concentrations modestly.
Diuretics causing electrolyte imbalance: monitor potassium and magnesium levels.
Antihypertensive agents: adjust blood pressure monitoring as additive effect possible.

Frequently Asked Questions

Ivabradine Brillpharma is prescribed to lower heart rate in adults with chronic stable angina and in patients with heart failure with reduced ejection fraction. By reducing the rate at which the heart beats, it helps relieve angina symptoms and may decrease hospitalizations in eligible heart‑failure patients.

Ivabradine selectively blocks the funny (If) current carried by HCN channels in the sinoatrial node. Inhibition of this inward sodium/potassium current slows spontaneous depolarisation, which reduces the heart’s pacing without affecting contractile force, blood pressure, or atrioventricular conduction.

The exact dose of Ivabradine Brillpharma is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate target, and tolerance. Dosage may be adjusted during therapy, and any changes should follow the prescriber’s instructions and local labeling.

Safety data for Ivabradine during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless specifically indicated by a qualified healthcare professional.

To request Ivabradine Brillpharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Ivabradine and beta‑blockers lower heart rate, but Ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and also reduce contractile force. Ivabradine may be added when beta‑blockers are insufficient or not tolerated.

Store Ivabradine Brillpharma at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, direct sunlight and excessive heat to maintain product stability.

Ivabradine Brillpharma is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Dosing times are typically spaced 12 hours apart, but the exact schedule is set by the prescribing clinician.

The most serious adverse events include severe symptomatic bradycardia, atrial fibrillation, and marked hypotension. Patients should be instructed to report any unusually slow heart rate, fainting, palpitations, or sudden drops in blood pressure promptly to their healthcare provider.

Ivabradine is contraindicated in patients with severe hypotension (systolic BP < 90 mmHg), sick sinus syndrome, second‑ or third‑degree atrioventricular block, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to the drug.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.